Evidence map›Paper›PMID 36828710›Full record

ReviewTrends in molecular medicine2023

The physiology of bilirubin: health and disease equilibrium.

Libor Vitek, Terry D Hinds, David E Stec, Claudio Tiribelli

Open access · greenAbstract readReview
In one paragraph

Review in Trends in molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 5 pooled it
21.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 5 syntheses or guidelines pooled it, 138 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Sex-specific associations of the bilirubin-to-albumin ratio with lung cancer risk: evidence from Cox regression and causal survival forest analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Observational
  17. Bilirubin: translational perspectives.Pediatric research · 2026
    Review
  18. Article
  19. Article
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 3 countries.

Libor VitekFourth Department of Internal Medicine and Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 120 00 Prague, Czech Republic.
Terry D HindsDepartment of Pharmacology and Nutritional Sciences, Barnstable Brown Diabetes Center, Markey Cancer Center, University of Kentucky, Lexington, KY 40508, USA.
David E StecDepartment of Physiology and Biophysics, Cardiorenal, and Metabolic Diseases Research Center, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Claudio TiribelliFondazione Italiana Fegato-ONLUS, Trieste, Italy. Electronic address: ctliver@fegato.it.
Charles University · CZFondazione Italiana Fegato · ITUniversity of Kentucky · USUniversity of Mississippi Medical Center · US

Funding

STRUCTURAL VASCULAR ADAPTATION OF THE MICROCIRCULATIONP01HL051971 · NHLBI · UNIVERSITY OF MISSISSIPPI MEDICAL CENTER · PI RECKELHOFF, JANE F · 1993 to 2018
$39.4M
The role of leptin in autoimmune-associated hypertensionP20GM104357 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI HALL, JOHN E · 2013 to 2022
$23.4M
Novel Liver Signaling Pathways Controlling AdiposityR01DK121797 · NIDDK · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI HINDS, TERRY D · 2020 to 2024
$2.2M
Antioxidant-PPARalpha interaction and hypertensionK01HL125445 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI HINDS, TERRY D · 2015 to 2019
$779k
NHLBI NIH HHS K01 HL125445NHLBI NIH HHS P01 HL051971NIDDK NIH HHS R01 DK121797NIGMS NIH HHS P20 GM104357
6 · The paper itself

Abstract

Bilirubin has several physiological functions, both beneficial and harmful. In addition to reactive oxygen species-scavenging activities, bilirubin has potent immunosuppressive effects associated with long-term pathophysiological sequelae. It has been recently recognized as a hormone with endocrine actions and interconnected effects on various cellular signaling pathways. Current studies show that bilirubin also decreases adiposity and prevents metabolic and cardiovascular diseases. All in all, the physiological importance of bilirubin is only now coming to light, and strategies for increasing plasma bilirubin levels to combat chronic diseases are starting to be considered. This review discusses the beneficial effects of increasing plasma bilirubin, incorporates emerging areas of bilirubin biology, and provides key concepts to advance the field.

Indexed as

BilirubinCardiovascular DiseasesHeme Oxygenase-1HumansReactive Oxygen SpeciesBilirubinHeme Oxygenase-1Reactive Oxygen SpeciesbilirubinBlvraBVRAcardiovascular diseasecell signalingheme oxygenaseHmox1HO-1metabolismnuclear receptors

Identifiers

PMID36828710
PMCPMC10023336
OpenAlexW4321503471

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.